Who are oxytetracycline, taro elixir's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tygacil, CHLORTETRACYCLINE HYDROCHLORIDE, Amikacin Injection, Minocycline (yes/no), Tobramycin once a day, DoxyPEP.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/oxytetracycline-taro-elixir.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

oxytetracycline, taro elixir — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

oxytetracycline, taro elixir (oxytetracycline, taro elixir) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: tetracycline antibiotic. Area: Infectious disease.

phase 3 tetracycline antibiotic 30S ribosomal subunit Infectious disease Small molecule Live · refreshed every 30 min

Target snapshot

oxytetracycline, taro elixir (oxytetracycline, taro elixir) — Laboratorios Goulart S.A.. Oxytetracycline is a broad-spectrum antibiotic that inhibits protein synthesis by binding to the 30S ribosomal subunit.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
oxytetracycline, taro elixir TARGET	oxytetracycline, taro elixir	Laboratorios Goulart S.A.	phase 3	tetracycline antibiotic	30S ribosomal subunit
Tygacil	TIGECYCLINE	Fresenius Kabi	marketed	Tetracycline-class Antibacterial [EPC]	30S ribosomal subunit	2005-01-01
CHLORTETRACYCLINE HYDROCHLORIDE	CHLORTETRACYCLINE HYDROCHLORIDE		marketed	Tetracycline	30S ribosomal subunit	1950-01-01
Amikacin Injection	Amikacin Injection	Murdoch Childrens Research Institute	marketed	Aminoglycoside antibiotic	Bacterial 30S ribosomal subunit
Minocycline (yes/no)	Minocycline (yes/no)	Medical University of South Carolina	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
Tobramycin once a day	Tobramycin once a day	Oslo University Hospital	marketed	Aminoglycoside antibiotic	Bacterial 30S ribosomal subunit
DoxyPEP	DoxyPEP	Chinese University of Hong Kong	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-10-24 — Tygacil · 8975242 · US
2029-02-05 — Tygacil · 7879828 · US
2030-10-08 — Tygacil · 8372995 · US
2033-04-07 — Tygacil · 9855335 · US

Sponsor landscape (tetracycline antibiotic class)

BioPharmX, Inc. · 2 drugs in this class
Hospital General de Mexicali · 1 drug in this class
Laboratorios Goulart S.A. · 1 drug in this class
National Taiwan University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). oxytetracycline, taro elixir — Competitive Intelligence Brief. https://druglandscape.com/ci/oxytetracycline-taro-elixir. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing